Study of Imatinib in Children With Neurofibromatosis and Airway Tumors

Phase 2

Withdrawn

• Conditions: Neurofibroma, Plexiform
• Interventions: Drug: Imatinib Mesylate

• Registration Number: NCT03688568
• Lead Sponsor: Indiana University

Brief Summary

The purpose of this study is to look at a subset of plexiform neurofibromas and determine if the airway tumors are more sensitive to imatinib therapy. Funding Source - FDA OOPD

Detailed Description

Not available

Basic Information
|
Recruitment & Eligibility
|
Study & Design
|
Trial Locations

Study Timeline

• Study Start: 2018-09-01
• Study First Submitted: 2018-09-11
• Study First Submitted QC: 2018-09-26
• Study First Posted: 2018-09-28
• Primary Completion: 2020-09-01
• Status Verified: 2021-02
• Last Update Submitted: 2021-02-09
• Last Update Posted: 2021-02-12
• Study Completion: 2021-09-01

Recruitment & Eligibility

• Status: WITHDRAWN
• Sex: All
• Target Recruitment: Not specified

Inclusion Criteria

1. Patients aged: > 6 months and < 12 years of age.

2. Diagnosis of neurofibromatosis type 1 (NF1).

3. Presence of symptomatic airway plexiform neurofibromas ; defined by abnormal sleep study or pulmonary function testing.

4. Patients must have measurable (> 1.5 cm in two dimensions or able to assess a minimum of 3 slices) disease by magnetic resonance imaging (MRI).

5. Patients must have a Karnofsky of > 70% or Lansky of > 50% and a life expectancy of > 2 months.

6. Adequate end organ function, defined as the following:

   total bilirubin < 1.5 x ULN, SGOT and SGPT < 2.5 x UNL, creatinine < 1.5 x ULN, ANC > 1.5 x 109/L, platelets > 100 x 109/L.

7. Patients must be able to swallow whole pills or crushed pills in a soft food such as pudding or apple sauce; or have other GI access such as a G-tube.

8. Written, voluntary informed consent/assent.

Read More

Exclusion Criteria

1. Patient has received any other investigational agents within 14 days of first day of study drug dosing.
2. Patient is < 5 years free of another primary malignancy except: if the other primary malignancy is not currently clinically significant nor requiring active intervention, or if other primary malignancy is a basal cell skin cancer or a cervical carcinoma in situ. Existence of any other malignant disease is not allowed.
3. Patient with Grade III/IV cardiac problems as defined by the New York Heart Association Criteria. (i.e., congestive heart failure, myocardial infarction within 6 months of study)
4. Patient has a severe and/or uncontrolled medical disease (i.e., uncontrolled diabetes, chronic renal disease, or active uncontrolled infection).
5. Patient has a known brain metastasis. Non-specific CNS changes on MRI/CT characteristic of NF1 are allowed, but not known CNS malignancies requiring therapeutic intervention.
6. Patient has known chronic liver disease (i.e., chronic active hepatitis, and cirrhosis).
7. Patient has a known diagnosis of human immunodeficiency virus (HIV) infection.
8. Patient received chemotherapy within 4 weeks (6 weeks for nitrosourea or mitomycin-C) prior to study entry.
9. Patient previously received radiotherapy to > 25 % of the bone marrow
10. Patient had a major surgery within 2 weeks prior to study entry.
11. Patient/parent with any significant history of non-compliance to medical regimens or with inability to grant reliable informed consent.
12. Patients who have or anticipate receiving permanent (or semi-permanent) metallic structures attached to their body. (e.g., braces on teeth, body piercings), which their physicians believe will interfere with the MRI.
13. Patient has an unstable airway requiring more urgent intervention or deemed unable to travel due to unstable airway by referring MD.

Read More

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
Imatinib Mesylate Arm	Imatinib Mesylate	Imatinib Mesylate, given daily orally, 55 mg PO BID, if tolerated for 2 weeks increase to 110 mg/m2 BID, and further increase to 165 and final dosage to 220 mg/m2 bid if tolerated. Can continue for 12 months.

Primary Outcome Measures

Name	Time	Method
Quantitative Functional Airway Response	12 months	Sleep study or pulmonary function test

Secondary Outcome Measures

Name	Time	Method
Radiologic response of tumor	12 months	Volumetric MRI measurements
Quality of Life Assessment	12 months	Quality of Life Questionnaire
Cytokine Biomarker	12 months	Immunoassay
Inflammatory Cell Biomarker	12 months	Flow cytometry

Trial Locations

Locations (1)

Riley Hospital for Children - Indiana University; 🇺🇸 Indianapolis, Indiana, United States